Mumbai, Dec 18 (PTI) SILVER SPOT (IN RS PER kg): 66526.00 STANDARD GOLD (99.5) : 49993.00 PURE GOLD (99.9) : 50194.00 PTI MUM SVC SHW SHW
Oslo [Norway], January 16 (ANI): Twenty-three people died in Norway within days of receiving their first dose of the Pfizer COVID-19 vaccine with 13 of those deaths apparently related to the side effects of the shots, New York Post reported citing the health officials.
On January 14, Adar celebrated his 40th birthday. His wife Natasha Poonawalla shared a lovely picture of the intimate celebration of Adar’s birthday. Their two sons and Adar’s father Cyrus Poonawalla are also present in the picture,
Kerala star Mohammed Azharuddeen made batting look easy on Wednesday as he smacked 10 sixes and 9 fours for an unbeaten 137 off 54 balls handing his team victory over Mumbai in just 16 overs in Syed Mushtaq Ali Trophy.
The couple have never been shy about their combined love of power. When they got engaged, Ivanka Trump said in an interview that she knew Kushner was the one when she found his ambition matched hers.
Prime Minister Narendra Modi, in a televised address before the vaccine rollout, said Covishield and Covaxin being made in India was an example the country's self-reliance.
Mumbai Police have annexed chats allegedly between Goswami and former BARC CEO Partho Dasgupta in court filings.
The compelling show stars Saif Ali Khan, Dimple Kapadia and Sunil Grover in key roles.
Washington [US], January 15 (ANI): China possibly carried out "genocide" against Uyghurs and other minority Muslims in its western region of Xinjiang, said a commission of the United States Congress in a new report.
Back in 2020, when the US was preparing for Presidential elections and Donald Trump was the sole Republican Party candidate for a second White House run, had taunted Kamala Harris for dropping out of the Democratic nomination race.
If the company's track record is anything to go by, the speed of the project and not the capacity to manufacture LCA should raise concerns
Czech automaker Skoda will launch the facelifted Kodiaq SUV in India, in the second half of 2021. In the latest development, a test mule of the upcoming car sans camouflage has been found testing on the roads, revealing its key design highlights. As per the pictures, it will have a blacked-out butterfly-shaped grille, redesigned alloy wheels, and taillights, among others. Here's our roundup.
The Mumbai police also submitted the status report of its investigation on Friday.
Our Health Editor Vaishali Sood, along with Dr Shahid Jameel, responds to your questions on COVID vaccines.
Democratic Representative Mikie Sherrill, a former U.S. Navy helicopter pilot, has accused some Republican lawmakers of helping Trump supporters, saying she saw colleagues leading groups on 'reconnaissance' tours on Jan. 5.
If Galileo were alive today, he would see not the stars and planets that he saw from his telescope but the millions of pieces of space debris and plastic hanging around in space today.
The humanitarian aspect of the visit has unfortunately not been highlighted by the KP Oli govt in Nepal.
Every one of the eight singles exponents – six in the men’s category, and two among the women, comprising the cream of Indian badminton – were sidelined before the completion of the second round matches
Udhampur, Jan 15 (PTI) A top Indian Army commander on Friday said the force has shown immense grit and determination to match the Chinese aggression in eastern Ladakh and gave a befitting reply, adding talks on the military standoff are being held with the PLA from a position of equivalence.
Washington [US], January 16 (ANI): US President Donald Trump's approval rating has plummeted to an all-time low, led by a dramatic drop in support among voters of his own party, following insurrection at the Capitol last week.
Despite efforts to procure Covid vaccine, some nations will only vaccinate 20% of populationCoronavirus – latest updatesSee all our coronavirus coverage The driver of a van containing Covid-19 vaccines from the Serum Institute of India flashes a victory sign as the vaccine boxes arrive in Amritsar. Photograph: Raminder Pal Singh/EPA There are triumphant scenes as lorries leave a vaccine plant in Pune, India, loaded with boxes that will prevent thousands of deaths. Adar Poonawalla, the owner and chief executive of the Serum Institute of India, poses on the tailgate of a truck, making the most of his company’s “proud and historic” moment as the potential saviour of the nation – and even a large chunk of the world. Poonawalla’s factory, the largest vaccine manufacturing complex in the world, is the best hope for immunisation for people in Africa and some low-income countries elsewhere – which could save them from the ravages of the coronavirus pandemic. The Serum Institute has been contracted to supply the UN-backed Covax initiative, which subsidises low-income countries, with 200m doses of Covid-19 vaccines with an option on 900m more. For a heart-stopping moment last week, it seemed that vaccine nationalism within India might slam the door. On 4 January, just after the Serum Institute got approval from the Indian regulator for the vaccine – made under licence from AstraZeneca – Poonawalla was reported as saying there was a condition attached, which was that only India could have the vaccine for the time being. Map of factories where the Oxford vaccine will be made The following day, he clarified the “confusion in the public domain” on Twitter, saying “exports of vaccines are permitted to all countries”. But the lorries are headed across India for now and the episode underlines the tension as every country with cash wades into the fight for vaccines, putting manufacturers under unprecedented pressure to deliver for them. As affluent Europe and North America scramble to deploy the Covid vaccines they have pre-bought – amid accusations that immunisation programmes are too slow and the wrong people are getting the jabs – there has been not a single shot in the arm in many countries elsewhere. Three vaccines have been approved in the west. Pfizer/BioNTech and Moderna are expensive and need long-term storage at -70C. Pfizer offered to sell the vaccine to South Africa at a 50% discounted price of $10 a shot, but was told the cost was still prohibitive. But Oxford/AstraZeneca’s vaccine is stable at fridge temperatures of 2-8C and AstraZeneca has promised not to make a profit for the duration of the pandemic. It aims to provide 3bn doses this year, made in factories around the world under licence. It is the mainstay of the Covax initiative, which has now bought a total of 1.97bn doses of four different vaccines to distribute when they become available. The AstraZeneca vaccine accounts for most of it. The Serum Institute has promised to make 100m doses for Covax of the AstraZeneca vaccine and a further 100m of the Novavax jab – if and when that is approved. Covax has an option on a further 900m doses of one or the other of those vaccines. Deliveries could start as early as February, said a spokesperson for Gavi, the vaccine alliance which is a partner in Covax. “We anticipate being able to provide each participating economy with the first tranche – enough to protect approximately 3% of the population – in the first half of 2021. This process could begin as early as February, pending favourable regulatory outcomes and the readiness of health systems and national regulatory systems in individual participating economies. “In terms of which vaccines will be rolled out to which countries, as well as timeframes, we hope to be able to share more on that very soon.” Seven countries have now given emergency authorisation to the Oxford/AstraZeneca vaccine or the Serum Institute version: the UK, India, Argentina, the Dominican Republic, El Salvador, Mexico and Morocco. The Carlos Slim Foundation in Mexico is licensed by AstraZeneca to supply 150m doses to Latin America. These countries could take delivery right away. But other countries without a regulatory body will be waiting for the World Health Organization to give the green light, which is said to need data from the Serum Institute. In what sounded like a nudge, the director general, Tedros Adhanom Ghebreyesus, said on 11 January it looked forward “to Serum Institute of India submitting full datasets for rapid assessment so WHO can determine whether we can recommend their AstraZeneca vaccine for international use”. default The AstraZeneca vaccine will also be manufactured by SKbioscience in Korea, BioKangtai in China, Siam BioScience and the local conglomerate SCG in Thailand and CSL Behring in Australia. The Fiocruz Institute in Brazil has signed a deal for 100m doses of the Serum Institute vaccine, which it will put into vials in a process known as “fill and finish”. In an attempt to queue-jump, the Brazilian president, Jair Bolsonaro, wrote to the Indian prime minister, Narendra Modi, on 9 January. “To enable the immediate implementation of our national immunisation programme, I would appreciate … the supply to Brazil, with the possible urgency and without jeopardising the Indian vaccination programme, of 2m doses,” Bolsonaro wrote. Brazil is also now buying 10m doses of the Russian Sputnik vaccine. It is late to the party. At the very end of last year, Argentina took delivery of 300,000 doses and has been immunising healthcare workers. The Russians claim it is 92% effective, but the data has not been published. A few middle-income countries have started vaccination programmes using the Pfizer/BioNTech jab. Mexico took delivery of 3,000 doses in December. Chile and Costa Rica have also started using the vaccine. Mexican officials have been to talk to their counterparts in Argentina about buying Sputnik. Chinese vaccines are also beginning to be used. Bahrain and the United Arab Emirates both gave emergency approval to the vaccine made by Sinopharm in December, which the manufacturers say is 86% efficacious, although – as with the Russian vaccine – the full data has not been made public. Turkey has bought the Chinese vaccine, and Morocco, Egypt and Nigeria have all been in discussions. There are other promising jabs on the way. Novavax aims to make 2bn doses for global use – but has not yet finished its trials. Covax has an option on 500m doses of the Janssen vaccine, which has the advantage of being one shot, but although results from phase 3 trials are expected within weeks, there are said to be manufacturing delays. It could be a major player, however. “Johnson & Johnson aims to provide global access to Janssen’s Covid-19 vaccine candidate, if proven to be safe and effective. We have committed to producing 1bn vaccines doses a year starting in 2021 and have expedited manufacturing scale-up to reach this goal,” said a spokesperson. “We are leveraging a global supply base for our vaccine candidate, including facilities in the United States, Europe, Asia and Africa.” David Salisbury, associate fellow of Chatham House’s global health programme and director of immunisation at the Department of Health until 2013, said that even if the amount of vaccine distributed across the world increased, not all countries would be able to run vaccination programmes for everyone who needed it. “There’s a huge gap between a desire to have vaccine and political statements that your country will have vaccine – and actually having contracts either in place yourself or on your behalf and the ability to pay for it – and much more, the ability to implement it,” he said. The vaccination against Covid-19 is not like running childhood vaccination programmes, but more similar to the effort to immunise against the seasonal flu. Most low-income countries do not have enough clinics or databases to tell them how to access those at risk. Countries that get enough vaccine for 20% of the population, which is what Covax hopes to provide eventually, will not be able to stop transmission. They will be in an “endless cycle”, said Salisbury – vaccinating health workers and those most at risk of dying, with more people getting older and moving into the at-risk groups all the time. The coronavirus is not going away, especially in low income countries. It could be argued the vaccines are just a temporary fix. “Predicting the future for vaccine campaigns in all parts of the world is something many of us are already thinking about. Will this become institutionalised as an annual vaccination programme for industrialised countries? Unless this virus goes away I think the answer is yes,” said Salisbury. “But what will the appetite be in low-income countries for resources that are already under huge pressure to be used for prevention of coronavirus?”
